Mohammad Sadeghi; Salimeh Jafari; Hadi Aligholi; Zahra Shayan; Alireza Keshavarz Bahaqiqat
Articles in Press, Accepted Manuscript, Available Online from 17 March 2025
Abstract
Background: Alzheimer's disease (AD) is a serious progressive neurodegenerative disorder that is characterized by memory loss and cognitive performance decline. one of the theories ...
Read More
Background: Alzheimer's disease (AD) is a serious progressive neurodegenerative disorder that is characterized by memory loss and cognitive performance decline. one of the theories to explain AD pathology is the emergence of abnormal hypometabolism. The current study aimed to investigate the association of cortical hypometabolism, and cognitive assessment tools in dementia spectrum.
Methods: Our cross sectional/longitudinal study used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), including 1048 subjects with 291 cognitively normal (CN), 579 mild cognitive impairment (MCI), and 178 AD. The FDG-PET data (as an indicator for hypometabolism) and cognitive assessment scores including Alzheimer's Disease Assessment Scale (ADAS11 and ADAS13 subtests), Montreal Cognitive Assessment (MoCA), Everyday Cognition Scale (ECog), and Mini-Mental State Exam (MMSE) were gathered. ANOVA, multiple regression, ROC and AUC analyses were used to analyze data.
Results: According to linear regression analysis, ADAS11, ADAS13, and MMSE predicted PET scores in the MCI group (p-values:0.002,0.002, 0.017), but MoCA predicted PET scores in the CN group (β=0.016, p=0.045). ADAS13 exhibited the greatest discriminative capacity (AUC=0.786), followed by ADAS11 (AUC=0.767), according to ROC analysis. Over time, PET scores declined significantly in all groups, with the AD group exhibiting the biggest fall. The PET scores of the CN and MCI groups were notably higher than those of the AD group at 24 months (p<0.001).
Conclusion: The ADAS11 and ADAS13 tests could distinguish between normal and abnormal hypometabolism. Additionally, ADAS13 has the best discriminative ability, which is useful for clinicians and researchers for early detection and monitoring of the AD spectrum.
